Amgen Inc. has garnered significant attention in recent times. The company's **Phase 3 Results** for **UPLIZNA** were positive and the drug met its study goal for a rare disease. Despite performing lower than the broader market, Amgen's experimental **obesity drug** and other medical stocks are outperforming. The company's **Tarlatamab** has received **FDA approval** for SCLC. There has been a spurt in Amgen's revenues and earnings due to update on its obesity drug. Encouraged by the weight-loss drug interim data, investors are eyeing the company's obesity drug payout. While the company suffered a drop in the general market, the recent **Q1 earnings** and obesity drug update caused a surge. The company has planned to present at the *Jefferies Global Healthcare Conference*. Amgen's **dividend growth** and weight-loss wild card make it a fantastic prospect. *Analysts estimate* reduction in earnings. Interestingly, **2024 second quarter dividend** has been announced. Despite a 6.5% dip since the last earnings report, good results from the new lung cancer study and updates on COPD, ASTHMA AND VASCULITIS research indicate a potentially strong Q4. Encouragement from the obesity drug has Amgen near a record high with a RS Rating Jump to 81.
Amgen AMGN News Analytics from Thu, 09 Nov 2023 06:15:22 GMT to Sat, 08 Jun 2024 15:04:59 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 4
